Clinical trials: Limited-stage Small-cell Lung Cancer
NSCLC
Perioperative Treatment Outcomes of Early NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies.
- Trial name
- Peri-R (NCT06610240)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
Multiomics Tumor Evolution Model of NSCLC
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be…
- Trial name
- NCT05352035
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Inoperable Early Stage Non-small Cell Lung Cancer
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC).
- Trial name
- PEARL-2 (NCT01138748)
- Testing
- hypofractionated radiation therapy
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Small Cell Lung Cancer
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)
This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer
- Trial name
- NCT00494026
- Testing
- pemetrexed, carboplatin, radiotherapy
- Where
- 12 sites in Italy, Poland and 2 more
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Anorexia, Cachexia
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy.
- Conditions
- Anorexia, Cachexia, Lung Cancer
- Trial name
- NCT00031785
- Testing
- megestrol acetate, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Non-small Cell Lung Cancer
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Analysis of driver gene variation in early stage non-small cell lung cancer
- Trial name
- NCT04266691
- Testing
- nonIntervention
- Volunteers
- 237 people
- Sponsor
- Zhejiang Cancer Hospital
Adaptive Radiotherapy, Stereotactic Body Radiotherapy
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or…
- Conditions
- Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
- Trial name
- NCT06542159
- Testing
- Online adaptive SBRT, Conventional SBRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.
- Trial name
- NCT00643318
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States, China
- Volunteers
- 40 people
- Sponsor
- Accuray Incorporated
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
- Trial name
- Eucalyptus (NCT06430866)
- Testing
- ABP 234, Pembrolizumab
- Where
- 128 sites in Argentina, Bulgaria and 16 more
- Volunteers
- 163 people
- Sponsor
- Amgen
Small-cell Lung Cancer
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
- Trial name
- NCT04691063
- Testing
- SHR-1316; Carboplatin; Etoposide；Radiotherapy, Palcebo; Carboplatin; Etoposide；Radiotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Small Cell Lung Cancer
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body.
- Trial name
- NCT04624204
- Testing
- Pembrolizumab 200 mg, Pembrolizumab 400 mg, Olaparib 300 mg BID
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 672 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01999881
- Testing
- exercise intervention, standard follow-up care, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01139944
- Testing
- DNA methylation analysis, polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lung Cancer
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554463
- Testing
- Filgrastim, Pegfilgrastim, Etoposide
- Where
- 14 sites in United States
- Volunteers
- 5 people
- Sponsor
- Radiation Therapy Oncology Group
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination) is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an anti-transforming growth factor beta (TGFB)…
- Trial name
- NCT02581787
- Testing
- Fresolimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Maximilian Diehn
Myelosuppression
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on…
- Trial name
- NCT06490081
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences